Stocktoria
Aclaris Therapeutics, Inc. ACRS
Aclaris Therapeutics, Inc. (ACRS) earns a Piotroski F-score of 2/9 (weak financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $7.8M at a -829.6% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.422 |
| Retained earnings / assets | -6.031 |
| EBIT / assets | -0.476 |
| Equity / liabilities | 1.797 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| ACRS | Aclaris Therapeutics, Inc. | 2/9 | -18.21 | — | -58.2% |
| COYA | Coya Therapeutics, Inc. | 2/9 | 5.24 | — | — |
| CRNX | Crinetics Pharmaceuticals, Inc. | 2/9 | 6.19 | — | — |
| ADAG | Adagene Inc. | 4/9 | -9.75 | — | — |
| XENE | Xenon Pharmaceuticals Inc. | 2/9 | 6.89 | — | — |
| ROIV | Roivant Sciences Ltd. | 1/9 | 18.07 | — | -71.6% |
| OVID | Ovid Therapeutics Inc. | 1/9 | 0.8 | — | -96.8% |
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.
FAQ
Is ACRS financially healthy?
Aclaris Therapeutics, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does ACRS pay a dividend?
No, Aclaris Therapeutics, Inc. does not currently pay a dividend.
How profitable is ACRS?
In FY2025, Aclaris Therapeutics, Inc. had a net margin of -829.6% and a return on equity of -63.0%.
What is the analyst price target for ACRS?
The average Wall-Street price target for Aclaris Therapeutics, Inc. is $10.00, about 71.2% above the recent price, from 10 analysts (consensus: strong buy).
Is ACRS a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Aclaris Therapeutics, Inc.: a Piotroski F-score of 2/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.